Elevated vascular endothelia growth factor-A in the serum and peritoneal fluid of patients with endometriosis
- PMID: 19821100
- DOI: 10.1007/s11596-009-0520-7
Elevated vascular endothelia growth factor-A in the serum and peritoneal fluid of patients with endometriosis
Abstract
There has been emergence of evidence suggesting that specific variants of the vascular endothelia growth factor (VEGF) family, based on their ability to regulate angiogenesis, would be pivotal in the pathogenesis of endometriosis. This study was aimed at determining whether high levels of VEGF-A could be found in the serum and peritoneal fluid (PF) of patients with endometriosis. VEGF-A levels were measured by enzyme-linked immunosorbent assay (ELISA) in serum and PF from 46 patients with surgically confirmed endometriosis, and 40 controls with no clinical evidence of the disease or detectable endometriotic lesions at the time of surgical examination. The results showed the mean VEGF-A levels were significantly higher in the serum and PF of patients with endometriosis than in the controls. The VEGF-A levels in the serum and PF of patients with severe endometriosis (stages III-IV) were significantly higher than in those with minimal endometriosis (P<0.001). It was concluded that endometriosis was associated with significant modulation in the levels of circulating VEGF-A.
Similar articles
-
The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions.Reproduction. 2006 Sep;132(3):501-9. doi: 10.1530/rep.1.01110. Reproduction. 2006. PMID: 16940291
-
Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis.Hum Reprod. 2003 Aug;18(8):1674-80. doi: 10.1093/humrep/deg326. Hum Reprod. 2003. PMID: 12871881
-
Higher activity by opaque endometriotic lesions than nonopaque lesions.Acta Obstet Gynecol Scand. 2004 Apr;83(4):375-82. doi: 10.1111/j.0001-6349.2004.00229.x. Acta Obstet Gynecol Scand. 2004. PMID: 15005786
-
IL-17: an important pathogenic factor in endometriosis.Int J Med Sci. 2022 Apr 11;19(4):769-778. doi: 10.7150/ijms.71972. eCollection 2022. Int J Med Sci. 2022. PMID: 35582411 Free PMC article. Review.
-
Multiplex immunoassays in endometriosis: An array of possibilities.Front Biosci (Landmark Ed). 2017 Jan 1;22(3):479-492. doi: 10.2741/4496. Front Biosci (Landmark Ed). 2017. PMID: 27814626 Review.
Cited by
-
Blood biomarkers for the non-invasive diagnosis of endometriosis.Cochrane Database Syst Rev. 2016 May 1;2016(5):CD012179. doi: 10.1002/14651858.CD012179. Cochrane Database Syst Rev. 2016. PMID: 27132058 Free PMC article.
-
Targeting NGF but not VEGFR1 or BDNF signaling reduces endometriosis-associated pain in mice.J Adv Res. 2025 Jul;73:593-605. doi: 10.1016/j.jare.2024.08.017. Epub 2024 Aug 12. J Adv Res. 2025. PMID: 39142441 Free PMC article.
-
Adenoviral vector encoding soluble Flt-1 engineered human endometrial mesenchymal stem cells effectively regress endometriotic lesions in NOD/SCID mice.Gene Ther. 2016 Jul;23(7):580-91. doi: 10.1038/gt.2016.30. Epub 2016 Mar 18. Gene Ther. 2016. PMID: 26990775
-
Down regulation of MiR-93 contributes to endometriosis through targeting MMP3 and VEGFA.Am J Cancer Res. 2015 Apr 15;5(5):1706-17. eCollection 2015. Am J Cancer Res. 2015. PMID: 26175939 Free PMC article.
-
Endoureterotomy is not a sufficient treatment for intrinsic ureteral endometriosis.Wideochir Inne Tech Maloinwazyjne. 2013 Sep;8(3):187-91. doi: 10.5114/wiitm.2011.33614. Epub 2013 Mar 5. Wideochir Inne Tech Maloinwazyjne. 2013. PMID: 24130631 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical